Comprehensive hormonal support for peri- and post-menopausal women. Skin quality, GH axis support, bone density, and hormonal signalling — without systemic HRT.
The female hormonal protocol targets the four major consequences of declining oestrogen: collagen loss and skin deterioration (GHK-Cu + Collagen), GH axis decline (Ipamorelin), HPG axis disruption (Kisspeptin-10), and bone density reduction (Collagen + IGF-1 elevation from Ipamorelin). Together these compounds address the core biology of the menopausal transition without requiring systemic oestrogen or progesterone.
This is not a replacement for HRT where HRT is appropriate — it is a complementary approach for women who cannot take HRT, prefer not to, or want additional support alongside it.
Kisspeptin neurons in the hypothalamus drive GnRH pulse generation. The decline of these neurons is one of the primary drivers of the erratic LH/FSH pulsatility seen in perimenopause and the eventual HPG axis quiescence of post-menopause. Kisspeptin-10 supplementation at physiological doses partially restores this signalling.
Crucially, Kisspeptin-10 works upstream — it stimulates the pituitary's own LH release rather than replacing it. This means the hormonal response is more physiological than direct LH injection and does not carry the same risks.
Oestrogen directly upregulates collagen synthesis — when oestrogen falls, collagen production drops significantly and skin begins to thin and lose elasticity rapidly. GHK-Cu partially compensates for this by directly upregulating TGF-β and fibronectin expression, restoring collagen I and III synthesis via pathways that bypass the oestrogen receptor. This makes it uniquely valuable in the post-menopausal context.
Full dosing, titration schedule, blood work timing and cycling notes are available inside the platform. Use the calendar to track your protocol.